Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT387 (Xiao luo ni) plus chidamide in relapsed/refractory non-Hodgkin lymphoma (phase I/II)
CTR20190947Phase 2Terminated
- Sponsor
- Chipscreen Biosciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of chiauranib in non-Hodgkin lymphoma (NHL), sponsored by Chipscreen Biosciences. Started May 2019; status: terminated.
02
Drugs
chiauranib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20190947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190947.